The record
| Class | metabolic |
|---|---|
| Also known as | FTPP (Fat-Targeted Proapoptotic Peptide), Prohibitin-TP01, Prohibitin-targeting peptide 1 |
| Chain length | - |
| Molecular weight | 2,557.21 Da |
| Half-life | Short (rapidly targets adipose vasculature) |
| Route | SC |
| Studied for | Obesity/weight loss (investigational - discontinued); Prostate cancer (investigational) |
| Research use | Anti-obesity drug development; Vascular targeting research; Prohibitin signaling studies |
| What has been shown | ~; Significant fat loss in obese rhesus monkeys; Improved insulin sensitivity; Reduced BMI |
| How it works | Chimeric peptidomimetic with two functional domains: (1) Homing peptide (CKGGRAKDC) that binds to prohibitin and annexin A2 receptors specifically expressed on blood vessels supplying white adipose tissue, and (2) Proapoptotic sequence D(KLAKLAK)2 that disrupts mitochondrial membranes upon internalization. Induces targeted apoptosis of fat tissue vasculature, causing fat cells to die from lack of |
| Patent status | MD Anderson / research patents |
| Regulatory status | development discontinued (2019) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 47%)
- Cognitive support (illness, 30%)
- Fat loss without muscle loss (illness, 30%)
- HIV-associated lipodystrophy (illness, 30%)
- Obesity/weight loss (illness, 100%)
- Prostate cancer (illness, 100%)
- Visceral adiposity reduction (illness, 30%)
- Weight gain or constant hunger (symptom, 50%)